Clinical Cancer Research Grants AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 14, 3881, June 15, 2008. doi: 10.1158/1078-0432.CCR-07-5095
© 2008 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hiwase, D. K.
Right arrow Articles by White, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiwase, D. K.
Right arrow Articles by White, D. L.

Cancer Therapy: Clinical

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

Devendra K. Hiwase1,2, Verity Saunders1, Duncan Hewett1, Amity Frede1, Stephanie Zrim1, Phuong Dang1, Laura Eadie1, L. Bik To1,2, Junia Melo1,2, Sharad Kumar1, Timothy P. Hughes1,2 and Deborah L. White1,2

Authors' Affiliations: 1 Division of Haematology, Institute of Medical and Veterinary Science and 2 Faculty of Health Science, Department of Medicine, University of Adelaide, Adelaide, South Australia, Australia

Requests for reprints: Timothy P. Hughes, Division of Haematology, Institute of Medical and Veterinary Science, Frome Road, Adelaide, South Australia 5000, Australia. Phone: 61-8-82223330; Fax: 61-8-82223139; E-mail: Timothy.hughes{at}imvs.sa.gov.au.


   Abstract
Top
 Abstract
Patients, Materials and Methods
 Results
 Discussion
 Disclosure of Potential...
 References
 
Purpose: The organic cation transporter OCT-1 mediates active transport of imatinib. We recently showed that low OCT-1 activity is a major contributor to suboptimal response in chronic myeloid leukemia (CML) patients treated with imatinib. The relevance of OCT-1 activity and efflux pumps in determining intracellular uptake and retention (IUR) of dasatinib was assessed.

Experimental Design: The effect of OCT inhibitors on [14C]dasatinib and [14C]imatinib IUR was compared using peripheral blood mononuclear cells from newly diagnosed CML patients. The role of efflux transporters was studied using ABCB1- and ABCG2-overexpressing cell lines and relevant inhibitors.

Results: Unlike imatinib, there was no significant difference in the dasatinib IUR at 37°C and 4°C (P = 0.8), and OCT-1 inhibitors including prazosin did not reduce dasatinib IUR significantly. In CML mononuclear cells, prazosin inhibitable IUR was significantly higher for imatinib than dasatinib (6.38 versus 1.48 ng/200,000 cells; P = 0.002; n = 11). Patients with high OCT-1 activity based on their imatinib uptake had IC50dasatinib values equivalent to patients with low OCT-1 activity. Dasatinib IUR was significantly lower in ABCB1-overexpressing cell lines compared with parental cell lines (P < 0.05). PSC833 (ABCB1 inhibitor) significantly increased the dasatinib IUR (P < 0.05) and reduced IC50dasatinib (from 100 to 8 nmol/L) in K562-DOX cell line. The ABCG2 inhibitor Ko143 significantly increased dasatinib IUR in ABCG2-overexpressing cell lines and reduced IC50dasatinib.

Conclusion: Unlike imatinib, dasatinib cellular uptake is not significantly affected by OCT-1 activity, so that expression and function of OCT-1 is unlikely to affect response to dasatinib. Dasatinib is a substrate of both efflux proteins, ABCB1 and ABCG2.

Imatinib mesylate (Glivec; Novartis Pharmaceutical) is the first line of treatment for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) patients. However, up to 15% to 25% of newly diagnosed CML-CP patients have primary resistance (failure to achieve any level of cytogenetic response at 6 months, lack of major cytogenetic response at 12 months, and absence of complete cytogenetic response at 18 months) to imatinib at 400 mg/d (1–3). Currently, mechanisms of primary imatinib resistance are not well defined, but kinase domain mutations do not appear to be an important cause (4). We have shown previously that the intrinsic sensitivity of imatinib (in vitro concentration of imatinib required to inhibit phosphorylation of the adaptor protein Crkl by 50%; IC50imatinib) is related to the intracellular uptake and retention (IUR) of imatinib, but IC50nilotinib is not correlated with nilotinib IUR (5). The organic cation transporter OCT-1 is an important mediator of active imatinib influx (5, 6). We have shown recently that the functional activity of the OCT-1 protein is a major determinant of molecular response to imatinib. Furthermore, the majority of CML patients who have suboptimal response to imatinib have low OCT-1 activity (7).

Dasatinib (Sprycel; formerly BMS-354825; Bristol-Myers Squibb) is a second-generation ABL and Src kinase inhibitor. In in vitro assay, it is approximately 300 times more potent than imatinib and active against most imatinib-resistant BCR-ABL mutants, except the T315I (8). In this current study, we have examined cellular influx and efflux of dasatinib and compared them with those already identified for imatinib. Understanding the dasatinib cellular transport mechanisms may facilitate the development of more effective treatment strategies based on transporter function.


   Patients, Materials and Methods
Top
 Abstract
 Patients, Materials and Methods
Results
 Discussion
 Disclosure of Potential...
 References
 
Cell lines. KU812 and K562 (BCR-ABL+) cell lines were obtained from the American Type Culture Collection. K562-DOX (ABCB1-overexpressing cell line) and VBL-100 (ABCB1-overexpressing variant of CCRF-CEM) were provided by Prof. Leonie Ashman (University of Newcastle). MEF3.8 and the ABCG2-overexpressing variant MEF-BCRP1 were kindly provided by Dr. John Allen (Centenary Institute).

All cell lines (except Mef3.8 and Mef-BCRP1) were cultured in RPMI 1640 supplemented by 10% FCS, L-glutamine (2 mmol/L; SAFC Bioscience), and penicillin/streptomycin (Sigma-Aldrich). Mef3.8 and Mef-BCRP1 cell lines were cultured in DMEM supplemented by 10% FCS, L-glutamine (2 mmol/L), and penicillin/streptomycin.

Patient samples. Blood was collected from CML-CP patients at presentation to the Royal Adelaide Hospital Haematology Clinic. All samples were collected with informed consent and importantly all samples were collected before commencement of imatinib therapy.

Mononuclear cells (MNC) were isolated from blood using Lymphoprep (Axis-Shield PoC) density gradient centrifugation. Experiments were done on cryopreserved cells following controlled rate freezing and storage in liquid nitrogen.

Kinase inhibitors. Dasatinib and [14C]dasatinib were kindly provided by Bristol-Myers Squibb. [14C]dasatinib was dissolved in ethanol at 1 mg/mL. Nonradiolabeled dasatinib was prepared at concentration of 10 mmol/L in DMSO (Merck K GaA).

Imatinib mesylate (Glivec) together with [14C]imatinib were kindly provided by Novartis Pharmaceuticals. Stock solutions of imatinib were prepared at 10 and 1 mmol/L in distilled water, sterile filtered, and stored at 4°C.

Drugs and inhibitors. The OCT inhibitors prazosin, progesterone (OCT-1 and OCT-3 inhibitors), procainamide (OCT-1 and OCT-2 inhibitors), N-methyl-nicotinamide (OCT-2, inhibitor), and corticosterone (OCT-3 inhibitor; Sigma Aldrich) were used at 100, 10, 100, 1,000, and 10 µmol/L, respectively. The ABCB1 inhibitor PSC833 (provided by Novartis Pharmaceuticals) and the fumitremorgin C analogue Ko143 (ABCG2 inhibitor was supplied by Dr. John Allen) were used at 10 and 0.5 µmol/L, respectively.

Western blot analysis. Western blot analysis for phosphorylated Crkl was done as described previously (9). Briefly, 2 x 106 patient MNC or 2 x 105 cells of BCR-ABL+ cell lines (K562, K562-DOX, and K562-ABCG2) were cultured in increasing concentrations of dasatinib (0-1,000 nmol/L) for 2 h. Cells were then washed with cold PBS and lysed in 20 µL Laemmli's buffer by boiling for 12 min. Protein lysates (10 µL equivalents to 1 x 106 patient MNC and 1 x 105 cells of cell lines) were resolved on a SDS/10% (w/v) polyacrylamide gel and electrophoretically transferred to polyvinylidene difluoride membrane (GE Healthcare). Following blocking, the membrane was probed with anti-Crkl antibody C20 (Santa Cruz Biotechnology), detected with ECF substrate (GE Healthcare), and analyzed by Fluor Imager analysis (Molecular Dynamics). Signals were quantified using Image Quant software (Molecular Dynamics), and the ratio of phosphorylated Crkl to total Crkl was determined. IC50 values were determined as the concentration of drug required to reduce phosphorylation of the adaptor protein Crkl (phosphorylated Crkl) by 50%.

Radiolabeled drug uptake and retention assay. The IUR assay was done as described previously (5). In brief, 2 x 105 cells were incubated at 37°C (unless specified otherwise) with varying concentrations of [14C]dasatinib or [14C]imatinib (0-2 µmol/L). Isotopes were resuspended to 1 mg/mL and specific activities were 3.3 MBq/mg for [14C]STI571 and 1.18 MBq/mg for [14C]dasatinib. After incubation, the cellular and aqueous phases were separated, and incorporation was determined using a Top Count Microplate Beta Scintillation counter (Perkin-Elmer) following the addition of Microscint 20 (Perkin-Elmer) scintillation fluid.

IUR assays were done in triplicate and repeated if the assay results were not concordant. K562 cells were used as a control for reproducibility of the assay, and if the results fell outside of the mean ± 2 SD, then the assay was repeated.

Overexpression of ABCG2 in the K562 cell line. K562 cells were transfected with pcDNA3-BCRP (ref. 10; kindly provided by Prof. Douglas Ross) using electroporation, selected with geneticin (G418, 500 µg/mL; Life Technologies/Invitrogen), and subcloned by limiting dilution in 96-well flat-bottomed culture plates. Positive subclones were identified by PCR screening, and overexpression of BCRP (ABCG2 protein) was assessed by using flow cytometry (anti-hBCRP1/ABCG2; R&D Systems).

Statistical analysis. The Mann-Whitney rank-sum or t tests were used to assess the difference between groups. P values < 0.05 were considered significant.


   Results
Top
 Abstract
 Patients, Materials and Methods
 Results
Discussion
 Disclosure of Potential...
 References
 
Dasatinib cellular uptake kinetics. To assess the effect of duration of culture on dasatinib IUR, K562 cells (2 x 105) were cultured with [14C]dasatinib (2 µmol/L) over a dynamic range of 5 minutes to 2 hours at 37°C and 4°C. Maximum dasatinib cellular uptake was achieved within 5 minutes at both temperatures, and there was minimal variation between 5 minutes and 2 hours (Supplementary Fig. S1A and S1B). Similarly findings were shown at lower concentration of dasatinib (0.5 and 1 µmol/L) and in HL-60 cell line (data not shown). For all subsequent experiments, the IUR assay was done over a 2-hour period to enable direct comparison of the IUR of dasatinib with the IC50dasatinib.

Dasatinib IUR was assessed in K562 cells (37°C and 4°C) and KU812 cells (37°C) over a range of dasatinib concentration (100-2,000 nmol/L). Dasatinib IUR at 15 minutes and at 2 hours was linear over the concentrations used for the study, suggesting that dasatinib cellular uptake is predominantly by diffusion (Supplementary Fig. S1C and S1D).

Effect of temperature on dasatinib IUR. It has been shown previously that the uptake of imatinib is temperature dependent, suggesting that the transport process is primarily active (5, 6). To assess the temperature dependence of dasatinib uptake, assays were done at 4°C and 37°C in MNC from CML patients (n = 10) and in cell lines. In contrast to the findings with imatinib, there was no significant difference in the dasatinib IUR at 37°C and 4°C (Supplementary Table S1).

Role of ABCB1 in dasatinib cellular efflux. K562-DOX (BCR-ABL+) and VBL-100 (BCR-ABL-) ABCB1-overexpressing cell lines along with their respective parental cell lines (K562 and CCRF-CEM) were used for assessing the role of ABCB1 in dasatinib cellular efflux. High expression of ABCB1 in K562-Dox cell line was shown by flow cytometry (CD243-PE; Beckman Coulter; Supplementary Fig. S2A and S2B).

The dasatinib IUR at 37°C was significantly lower in K562-DOX (P = 0.002, 0.003, and 0.002 at 0.5, 1, and 2 µmol/L, respectively) and VBL-100 (P < 0.001, P < 0.001, and P = 0.03) than in the respective parental cell lines (Fig. 1A and B ). However, at 4°C, there was no significant difference observed (P > 0.05; Fig. 1A and B). PSC833, an analogue of cyclosporine and a potent ABCB1 inhibitor (11), significantly increased dasatinib IUR in K562-DOX (P = 0.006, P < 0.001, and P < 0.001 at 0.5, 1, and 2 µmol/L, respectively) and VBL-100 cell lines (P = 0.04, 0.02, and 0.004; Fig. 2A and B ) but not in the parental cell lines K562 and CEM (P = 0.3 and 0.6).


Figure 1
View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Comparison of dasatinib IUR at 37°C and 4°C in ABCB1-overexpressing cell lines compared with their parental cell lines. A, at 37°C, dasatinib IUR (0.5, 1, and 2 µmol/L) is significantly lower (P = 0.002, 0.003, and 0.002, respectively) in K562-DOX compared with the parental cell line K562 (n = 5). However, at 4°C, there is no significant difference in IUR (P = 0.41 and 0.18 at 1 and 2 µmol/L dasatinib, respectively), except at 0.5 µmol/L (P = 0.02; n = 4). B, at 37°C, dasatinib IUR (0.5, 1, and 2 µmol/L) is significantly lower (P < 0.001, P < 0.001, and P = 0.03, respectively) in VBL-100 compared with the parental cell line CCRF-CEM (n = 5). However, at 4°C, there is no significant difference (P = 0.23, 0.15, and 0.38 at 0.5, 1, and 2 µmol/L dasatinib, respectively; n = 3) in dasatinib IUR between the two cell lines.

 

Figure 2
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Effect of PSC-833 (ABCB1 inhibitor) on dasatinib IUR in K562-DOX and VBL-100 cell lines. PSC-833 significantly increased dasatinib IUR in (A) K562-DOX cell line (P = 0.006, P < 0.001, and P < 0.001 at 0.5, 1, and 2 µmol/L dasatinib, n = 5) and (B) VBL-100 cell line (P = 0.04, 0.02, and 0.004 at 0.5, 1, and 2 µmol/L dasatinib; n = 5). C, Western blot analysis. i and ii, Western blots; iii, densitometry analysis of blots i and ii. IC50dasatinib in K562-DOX cell line is higher than K562 (100 versus 7 nmol/L) and PSC833 reduced IC50dasatinib in K562-DOX (100 to 3 nmol/L; i and iii) but not in K562 cell line (7 versus 8 nmol/L; ii and iii).

 
Effect of inhibition of ABCB1 on the IC50dasatinib. The IC50dasatinib was assessed in K562 and K562-DOX with and without the addition of PSC833. In the absence of PSC833, IC50dasatinib was a markedly higher in K562-DOX compared with K562 (100 versus 7 nmol/L). The addition of PSC833 reduced the IC50dasatinib for K562-DOX to 8 nmol/L (Fig. 2C, i and iii) but did not change significantly in K562 cells (7 versus 8 nmol/L; Fig. 2C, ii and iii). These data indicate that dasatinib is transported by ABCB1 and that high expression levels of this protein can translate to significant changes in IC50dasatinib, which can be modulated by the use of ABCB1 inhibitors.

Role of ABCG2 in dasatinib cellular efflux. Interactions of ABCG2 with imatinib have been noted previously (12–14). To assess the effect of ABCG2 on the intracellular concentration of dasatinib, the IUR assay was done in Mef3.8 (mouse embryonic fibroblast), Mef-BCRP1 (ABCG2-overexpressing variant), and K562 and K562-ABCG2 cell lines with and without Ko143 (ABCG2 inhibitor). ABCG2 overexpression was confirmed by flow cytometry (Supplementary Fig. S2C and S2D).

The dasatinib IUR (2 µmol/L) was significantly lower in the Mef-BCRP1 cell line compared with parental cell line (21.96 versus 40.03 ng/200,000 cells; P = 0.016) and Ko143 significantly increased the dasatinib IUR in the Mef-BCRP1 cell line (21.96 versus 45.67 ng/200,000 cells; P = 0.007; Fig. 3A ) but not in the parental cell line (40.03 versus 52.88 ng/200,000 cells; P = 0.1). Similarly, dasatinib IUR was lower, but not significantly so, in the K562-ABCG2 cell line compared with the parental K562 (23.52 versus 26.26 ng/200,000 cells; P = 0.1), and Ko143 significantly increased the dasatinib IUR in the K562-ABCG2 cell line (23.52 versus 30.29 ng/200,000 cells; P = 0.03; Fig. 3B) but not in parental cell line (26.26 versus 25.23 ng/200,000 cells; P = 0.78).


Figure 3
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Effect of ABCG2 protein overexpression on dasatinib IUR. A, dasatinib IUR is significantly less in Mef-BCRP1 (21.96 versus 40.03 ng/200,000 cells; P = 0.016) compared with the parental cell line (Mef3.8) and Ko143 (ABCG2 inhibitor) significantly increased dasatinib IUR in Mef-BCRP1 cells (P = 0.007) but not in the parental cell line (n = 5). B, dasatinib IUR is lower in K562-ABCG2 (23.52 versus 26.62 ng/200,000 cells; P = 0.1) cells compared with the parental cell line, and Ko143 significantly increased dasatinib IUR in K562-ABCG2 cell line (P = 0.03) but not in parental cell line (n = 4). C, Western blot analysis. i and ii, Western blots; iii, densitometry analysis of blots i and ii. IC50dasatinib is markedly higher in K562-ABCG2 cell line compared with K562 (25 versus 11 nmol/L) and Ko143 reduced IC50dasatinib in K562-ABCG2 cell line (25 versus 10.5 nmol/L; i and iii) but not in parental cell line (11 versus 11.5 nmol/L; ii and iii).

 
In keeping with these data, the IC50dasatinib was higher in the K562-ABCG2 cell line compared with K562 (25 versus 11 nmol/L). Ko143 reduced the IC50dasatinib in K562-ABCG2 (25 versus 10.5 nmol/L; Fig. 3C, i and iii) but did not change the IC50dasatinib in K562 (11 versus 11.5 nmol/L; Fig. 3C, ii and iii).

These data suggest that expression of high levels of ABCG2 protein reduce dasatinib IUR, resulting in an increase in the IC50dasatinib. We have shown that this effect can modulated using ABCG2 inhibitors.

Effect of OCT inhibitors on dasatinib cellular uptake. To assess the role of OCT on dasatinib cellular uptake, the dasatinib IUR was compared with the imatinib IUR in the MNC of CML-CP patients in the presence and absence of known OCT inhibitors. There was no significant difference between the uptake of imatinib (2 µmol/L) and dasatinib (2 µmol/L) in CML MNC (mean imatinib IUR, 20.4 ng/200,000 cells; mean dasatinib IUR, 16.20 ng/200,000 cells; P = 0.1; Fig. 4A ) over the 2-hour period. The addition of prazosin, an inhibitor of both OCT-1 (IC50, 1.8 µmol/L) and OCT-3 (IC50, 13 µmol/L), did not reduce the dasatinib IUR significantly (at 2 µmol/L and 250 nmol/L; P = 0.6 and 0.23, respectively) nor interpatient variability (Fig. 4A-C; Table 1 ). However, in keeping with our previous findings, prazosin significantly reduced the IUR of imatinib to 13.33 ng/200,000 cells (P = 0.005) and reduced interpatient variability (Fig. 4A-C; Table 1). In addition, procainamide, progesterone, corticosterone, and N-methyl-nicotinamide did not reduce the dasatinib IUR in KU812 cells (P = 0.4, 0.9, 0.8, and 0.1, respectively) and CML MNC cells (Table 1).


Figure 4
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Effect of OCT inhibitors on dasatinib and imatinib IUR. A, in MNC of newly diagnosed CML-CP patients (n = 11), prazosin (potent OCT-1 and weak OCT-3 inhibitor) significantly reduced imatinib IUR and reduced interpatient variability; however, it neither reduced dasatinib IUR nor variability in dasatinib IUR. B, there is significant interpatient variation in prazosin inhibitable (OCT-1 activity dependent) imatinib IUR. However, prazosin inhibitable dasatinib IUR is minimal with less interpatient variation. C, prazosin inhibitable (OCT-1 activity dependent) imatinib IUR is significantly higher than prazosin inhibitable dasatinib IUR (P = 0.002). D and E, KU812 cell line: prazosin did not reduce dasatinib IUR significantly at 100 nmol/L (1.2 ± 0.3 versus 1.3 ± 0.5 ng/200,000 cells; P = 0.9), 200 nmol/L (2.4 ± 0.41 versus 1.9 ± 0.8 ng/200,000 cells; P = 0.3), 500 nmol/L (5.82 ± 1.2 versus 5.94 ± 0.56 ng/200,000 cells; P = 0.8), 1 µmol/L (11.33 ± 2.7 versus 11.28 ± 1.6 ng/200,000 cells; P = 0.9), and 2 µmol/L (21.3 ± 3.3 versus 18.74 ± 2.61 ng/200,000 cells; P = 0.21). Similarly, procainamide (OCT-1 and OCT-2 inhibitors) did not reduce dasatinib IUR at 100 nmol/L (1.2 ± 0.3 versus 1.3 ± 0.25 ng/200,000 cells; P = 0.7), 200 nmol/L (2.4 ± 0.41 versus 2.2 ± 0.2 ng/200,000 cells; P = 0.5), and 2 µmol/L (21.3 ± 3.3 versus 20.5 ± 1.6 ng/200,000 cells; P = 0.4). *, effect of procainamide on dasatinib IUR was not assessed at 0.5 and 1 µmol/L.

 

View this table:
[in this window]
[in a new window]

  		Table 1. Effect of OCT inhibitors on [14C]dasatinib (250 nmol/L and 2 µmol/L) and [14C]imatinib (2 µmol/L) IUR in MNC of CML-CP patients

 
[14C]dasatinib has low specific activity. Therefore, at lower concentration, subtle effect of OCT inhibitors on dasatinib IUR could be missed; hence, dasatinib IUR was studied at 2 µmol/L. However, therapeutically achievable dasatinib concentration is 100 to 180 nmol/L (15, 16); hence, we have also compared the effect of OCT inhibitors at lower concentration. Prazosin, procainamide, and other OCT inhibitors did not reduce dasatinib IUR at 250 nmol/L in MNC of CML patients (n = 5; Table 1). Similarly, prazosin and procainamide did not reduce dasatinib IUR in KU812 cell line at 100 nmol/L (P = 0.9 and 0.76, respectively), 200 nmol/L (P = 0.29 and 0.50, respectively), and 2 µmol/L (P = 0.21 and 0.72, respectively; Fig. 4D and E).

We recently defined the OCT-1 activity (prazosin inhibitable imatinib IUR) as the difference between imatinib IUR in the presence and absence of prazosin and showed that patients with high OCT-1 activity (≥7.2 ng/200,000 cells) have superior molecular responses to imatinib compared with patients with low OCT-1 activity (<7.2 ng/200,000 cells; ref. 7). In this current analysis, we show that prazosin inhibitable IUR was significantly higher for imatinib compared with dasatinib (6.38 versus 1.48 ng/200,000 cells; P = 0.002; n = 11; Fig. 4B and C).

We have shown previously that patients with low IC50imatinib (below median) have significantly higher OCT-1 activity than patients with high IC50imatinib (7). However, IC50dasatinib in patients with high OCT-1 (n = 12) and low OCT-1 (n = 14) activity (2.0 versus 2.5 nmol/L; P = 0.3) was not significantly different in CML-CP patients. As shown in Fig. 5A , imatinib IUR was significantly higher in patients with high OCT-1 activity compared with patients with low OCT-1 activity; however, there was no significant difference in dasatinib IUR between the two groups (Fig. 5B).


Figure 5
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Effect of OCT-1 activity on imatinib and dasatinib IUR in MNC of CML-CP patients. A, dasatinib IUR is not significantly different between patients with high OCT-1 activity (≥7.2 ng/200,000 cells; n = 12) and low OCT-1 activity (<7.2 ng/200,000 cells; n = 14). B, imatinib IUR (0.5, 1, and 2 µmol/L) is significantly higher in patients with high OCT-1 activity compared with patients with low OCT-1 activity.

 
Correlation between dasatinib IUR and IC50dasatinib. We have performed IC50dasatinib and dasatinib IUR in MNC of newly diagnosed CML-CP patients (n = 18) before treatment. The median IC50dasatinib was 2.20 nmol/L and median dasatinib IUR was 16.33 ng/200,000 cells at 2 µmol/L dasatinib. In contrast to previous observations with imatinib, there was no correlation between dasatinib IUR and IC50dasatinib, suggesting that in newly diagnosed CML-CP patients dasatinib IUR is a not a major contributor to the interpatient variability observed in the IC50dasatinib.


   Discussion
Top
 Abstract
 Patients, Materials and Methods
 Results
 Discussion
Disclosure of Potential...
 References
 
Significant numbers of newly diagnosed CML-CP patients respond to imatinib; however, responses are variable, with up to 30% failing to achieve major molecular responses by 24 months (17). We have shown previously that IC50imatinib in MNC of CML-CP patients at diagnosis predicts molecular response in newly diagnosed CML patients treated with imatinib (9). We (5) and Thomas et al. (6) have shown that imatinib uptake is an active process and that the major active protein involved in imatinib uptake is OCT-1. We also showed that OCT-1-mediated cellular uptake is key determinant of imatinib IUR and interpatient variation in IC50imatinib (5). In our recent article, we have shown that most patients who have suboptimal molecular response to standard dose of imatinib have low OCT-1 activity measured in MNC at diagnosis (in vitro assay calculated as [14C]imatinib IUR with and without prazosin; ref. 7). In a randomized phase II trial, dasatinib was more effective than high-dose imatinib (800 mg/d) in patients resistant to conventional dose of imatinib (400-600 mg/d; ref. 18). Here, we have assessed the effect of OCT-1 activity on dasatinib cellular uptake.

In this study, we have shown that dasatinib cellular uptake is rapid, occurring within 5 minutes. We (5) and others (6) have shown previously that the intracellular concentration of imatinib achieved over a 2-hour period is significantly lower at 4°C than at 37°C. In contrast, this current study revealed no significant difference in the intracellular concentration of dasatinib achieved between 37°C and 4°C in MNC of CML patients and cell lines. Dasatinib IUR was linear over the range of drug concentrations tested at both temperatures. These findings suggest that, in contrast to imatinib, dasatinib cellular uptake is predominantly a passive process.

As reported previously (5, 6), the OCT-1 inhibitor prazosin significantly reduce the imatinib IUR and remove the observed interpatient variability. However, the addition of prazosin did not reduce dasatinib IUR (P = 0.63) nor reduce interpatient variability. Furthermore, the prazosin inhibitable IUR (OCT-1 activity) was significantly higher for imatinib compared with dasatinib (P = 0.002). In contrast to imatinib, dasatinib IUR was not significantly higher in patients with high OCT-1 activity (imatinib) compared with patients with low OCT-1 activity (imatinib). Unlike IC50imatinib (7), IC50dasatinib was not significantly different in patients with high and low OCT-1 activity. These data suggest that, in contrast to imatinib (5, 6), dasatinib cellular uptake is not OCT-1 dependent. Using a panel of OCT inhibitors (OCT-1, OCT-2, and OCT-3 inhibitors), we have also shown that dasatinib cellular uptake is not OCT-2 or OCT-3 dependent.

We have shown previously that OCT-1 mRNA level correlates with OCT-1 activity (r = 0.378; P = 0.002) and patients with high OCT-1 activity have superior molecular responses to imatinib compared with patients with low OCT-1 activity, but this difference could be partially overcome by the use of higher doses of imatinib (7). Unlike imatinib, dasatinib cellular uptake is not significantly affected by OCT-1 activity, so that expression and function of OCT-1 is unlikely affect response to dasatinib.

We (5) have shown previously that IC50imatinib correlates strongly with imatinib IUR; however, there is no correlation between nilotinib IUR and IC50nilotinib. We now show that there is also no correlation between dasatinib IUR and IC50dasatinib in MNC of CML patients. This may suggest that, in newly diagnosed CML-CP patients, variations in dasatinib IUR may not be an important determinant of intrinsic sensitivity to dasatinib (IC50dasatinib). From a clinical perspective, it is important to recognize that the median IC50dasatinib in newly diagnosed CML-CP patients is 2.20 ± 0.84 nmol/L, which is significantly below the dasatinib concentration achieved in patients (15). Hence, unlike imatinib, interpatient variability in IC50dasatinib and IUR is unlikely to be clinically significant for newly diagnosed CML patients receiving dasatinib. These findings are based on MNC and not on leukemic progenitor or stem cells. Similar studies in more primitive stem cells are in progress at our centre.

Efflux proteins belong to the family of ATP-binding cassette transporter, comprising seven subfamilies (ABCA-ABCG), and encoded by 48 genes. ABCB1, ABCC1, and ABCG2 are expressed at high levels on hematopoietic primitive cells (19, 20). There are multiple studies showing that imatinib is a substrate for ABCB1 (6, 21–24). Here, we show that the dasatinib IUR is significantly lower in ABCB1-overexpressing cell lines compared with their parental cell lines. We have also shown that PSC833 significantly increases the dasatinib IUR in an ABCB1-overexpressing cell lines and reduces the IC50dasatinib in K562-DOX cell line. This data suggest that dasatinib is a substrate for ABCB1.

There are several clinical implications of these findings. Dasatinib induces rapid hematologic and cytogenetic response in patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia, who are resistant or intolerant to imatinib (25). However, ATP-binding cassette transporters are highly expressed in brain and testes; hence, achieving adequate concentrations of dasatinib in testes and the central nervous system to control or prevent relapse at these extramedullary sites may be difficult. This could potentially be enhanced by drugs that inhibit ABCB1 activity, such as cyclosporine (26) or the proton pump inhibitors (27). ABCB1 is also expressed in gastrointestinal tract; similar considerations apply to gastrointestinal uptake. Polymorphisms or mutations that affect ABCB1 activity and overexpression of ABCB1 may all be relevant to the clinical efficacy of dasatinib. However, the importance of ABCB1 expression in the gastrointestinal tract remains uncertain. Recently, Kamath et al. (28) reported that there was no significant difference in the amount of dasatinib unabsorbed in gastrointestinal tract in P-glycoprotein (ABCB1) knockout mice and wild-type mice.

ABCG2 (BCRP1) is highly expressed on normal hematopoietic stem cells (29) and CML CD34+ cells (14). The role of ABCG2 in imatinib transport is controversial. Houghton et al. (13) and Jordanides et al. (14) reported that imatinib is a potent inhibitor but not a substrate of ABCG2, whereas Burger et al. (12) reported that imatinib is a substrate of ABCG2. Here, we have shown that at 37°C dasatinib IUR is lower in ABCG2-overexpressing cell lines compared with the parental line, and Ko143 (ABCG2 inhibitor) significantly increased dasatinib IUR in Mef-BCRP1 and K562-ABCG2 cell lines. The IC50dasatinib was higher in K562-ABCG2 compared with K562 and was reduced by Ko143, suggesting that dasatinib is also transported by ABCG2.

ABCG2 protein is susceptible to mutation at amino acid position R482, which affects functional characteristic of protein (30) and may lead to discrepancy between protein expression and activity. We are currently addressing if mutation in ABCG2 protein and protein expression level affect the dasatinib cellular efflux.

Knowledge of the cellular uptake/efflux pathways of the tyrosine kinase inhibitor and activity/expression of these pumps in individual patients may help us to individualize treatment. Currently, in newly diagnosed CML-CP patients, apart from clinical assessment (stage, duration of disease, prior treatment, and Sokal score), we also evaluate IC50 and IUR of three tyrosine kinase inhibitors (imatinib, dasatinib, and nilotinib), OCT-1 activity (imatinib), and OCT-1 mRNA level.

In summary, we have shown for the first time that dasatinib is a substrate of the ABCB1 and ABCG2 transporters in leukemic cells. We have also shown that dasatinib cellular influx is predominantly passive and not OCT-1, OCT-2, or OCT-3 dependent. We have suggested previously that OCT-1 activity should be considered in determining the optimal dose of imatinib for newly diagnosed patients. Our findings here provide evidence that consideration of OCT-1 activity is not likely to be relevant to dasatinib. However, these findings will need to be confirmed in a prospective study.


   Disclosure of Potential Conflicts of Interest
Top
 Abstract
 Patients, Materials and Methods
 Results
 Discussion
 Disclosure of Potential...
References
 
D.L. White has received commercial research support from Novartis and Bristol-Myers Squibb and honoraria from Novartis. T.P. Hughes has received commercial research grants and honoraria from and consulted with Bristol-Myers Squibb and Novartis.


   Acknowledgments
 
We thank Prof. Douglas D. Ross (University of Maryland School of Medicine, Greenebaum Cancer Center) for kindly providing the ABCG2 plasmids and Prof. Andrew Somogyi (Discipline of Pharmacology, University of Adelaide) for discussion and suggestions.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Received 12/13/07; revised 3/16/08; accepted 3/18/08.


   References
Top
 Abstract
 Patients, Materials and Methods
 Results
 Discussion
 Disclosure of Potential...
 References
 

  1. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–20.[Abstract/Free Full Text]
  2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–17.[Abstract/Free Full Text]
  3. Shah NP. Medical Management of CML. Hematology Am Soc Hematol Educ Prog 2007;2007:371–5.
  4. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006;20:29–41.[CrossRef][Medline]
  5. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697–704.[Abstract/Free Full Text]
  6. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–45.[Abstract/Free Full Text]
  7. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064–72.[Abstract/Free Full Text]
  8. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500–5.[Abstract/Free Full Text]
  9. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520–6.[Abstract/Free Full Text]
  10. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:15665–70.[Abstract/Free Full Text]
  11. te Boekhorst PA, van Kapel J, Schoester M, Sonneveld P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol 1992;30:238–42.[CrossRef][Medline]
  12. Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940–2.[Abstract/Free Full Text]
  13. Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004;64:2333–7.[Abstract/Free Full Text]
  14. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108:1370–3.[Abstract/Free Full Text]
  15. Bullock JM, Noory C, Men A, et al. Clinical pharmacology review: Sprycel, dasatinib. Application number 21-986. U.S. Food and Drug Administration, Center for Drug Evaluation and Research; 2006.
  16. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532–9.[Abstract/Free Full Text]
  17. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080–5.[Abstract/Free Full Text]
  18. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007;109:5143–50.[Abstract/Free Full Text]
  19. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85–94.[CrossRef][Medline]
  20. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275–84.[CrossRef][Medline]
  21. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003;304:1085–92.[Abstract/Free Full Text]
  22. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401–8.[CrossRef][Medline]
  23. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368–73.[Abstract/Free Full Text]
  24. Widmer N, Colombo S, Buclin T, Decosterd LA. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003;102:1142.[Free Full Text]
  25. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309–15.[Abstract/Free Full Text]
  26. Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306–14.[Abstract/Free Full Text]
  27. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577–82.[Abstract/Free Full Text]
  28. Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008;61:365–76.[CrossRef][Medline]
  29. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028–34.[CrossRef][Medline]
  30. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001;61:6635–9.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. S. Lagas, R. A.B. van Waterschoot, V. A.C.J. van Tilburg, M. J. Hillebrand, N. Lankheet, H. Rosing, J. H. Beijnen, and A. H. Schinkel
Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
Clin. Cancer Res., April 1, 2009; 15(7): 2344 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
D. White, P. Dang, K. G. Obbink, A. Frede, C. Kok, T. P Hughes, and R. D'Andrea
Enhancing the Functional Activity of the OCT-1 Influx Pump May Overcome the Negative Impact of Low OCT-1 Activity in Imatinib Treated CML Patients
Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 723 - 723.
[Abstract]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hiwase, D. K.
Right arrow Articles by White, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiwase, D. K.
Right arrow Articles by White, D. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online